Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in AL Amyloidosis
NCT02841033Phase 2Completed
- Sponsor
- Boston Medical Center
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in amyloid light chain amyloidosis, sponsored by Boston Medical Center. Primary endpoint: Number of Patients Who Respond to Treatment at 3 months. Started Mar 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02841033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841033.